The Breast
Volume 20, Issue 1 , Pages 34-38 , February 2011

Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer

  • Rosalba Torrisi

      Affiliations

    • Research Unit of Medical Senology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
    • Department of Medicine, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
    • Corresponding Author InformationCorresponding author. Present address: Department of Oncology and Hematology, Istituto Clinico Humanitas, Viale A. Manzoni 56, 20089 Rozzano, Milano, Italy. Tel.: +39 02 82244502; fax: +39 02 82244590.
    • ,
  • Emilia Montagna

      Affiliations

    • Research Unit of Medical Senology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
    • Department of Medicine, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
    • ,
  • Eloise Scarano

      Affiliations

    • Research Unit of Medical Senology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
    • Department of Medicine, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
    • ,
  • Silvia Dellapasqua

      Affiliations

    • Research Unit of Medical Senology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
    • Department of Medicine, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
    • ,
  • Giuseppe Cancello

      Affiliations

    • Research Unit of Medical Senology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
    • Department of Medicine, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
    • ,
  • Monica Iorfida

      Affiliations

    • Research Unit of Medical Senology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
    • Department of Medicine, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
    • ,
  • Alberto Luini

      Affiliations

    • Division of Senology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
    • ,
  • Paolo Veronesi

      Affiliations

    • Division of Senology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
    • University of Milan School of Medicine, via Festa del Perdono 7, 20135 Milano, Italy
    • ,
  • Giuseppe Viale

      Affiliations

    • Division of Pathology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
    • University of Milan School of Medicine, via Festa del Perdono 7, 20135 Milano, Italy
    • ,
  • Aron Goldhirsch

      Affiliations

    • Department of Medicine, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
    • ,
  • Marco Colleoni

      Affiliations

    • Research Unit of Medical Senology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
    • Department of Medicine, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy

Received 10 March 2010 ,Revised 12 May 2010 ,Accepted 15 June 2010.

References 

  1. Hortobagyi GN. Anthracyclines in the treatment of breast cancer: an overview. Drugs. 1997;54(Suppl. 4):1–7
  2. Swain SM, Whaley FS, Ewee MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869–2879
  3. Sparano JA, Winer EP. Liposomal anthracyclines for breast cancer. Semin Oncol. 2001;28(Suppl. 12):32–40
  4. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours. Drugs. 1997;54(Suppl. 4):15–21
  5. O’Brien MER, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCL (Caelyx/Doxil) versus conventional doxorubicin for first line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440–449
  6. Verma S, Dent S, Chow BJW, Rayson D, Safra T. Metastatic breast cancer: the role of pegylated doxorubicin after conventional anthracyclines. Cancer Treat Rev. 2008;34:391–406
  7. Srimuninnimit V, Sinralantana P, Bhothisuwan K, Pattaranutaporn P, Chakarapee-Sinsuk S, Akewanlop C, et al. Phase II study with combination of pegylated liposomal doxorubicin (caelyx) and cyclophosphamide (CC) in locally advanced breast cancer (LABC). Proc Am Soc Clin Oncol. 2002;21:70
  8. Grogas H, Papadimitriou C, Kalofonos HP, Bafaloukos D, Fountzilas G, Tsavdaridis D, et al. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx®) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol. 2002;13:1737–1742
  9. Rossi D, Baldelli AM, Casadei V, Fedeli SL, Alessandroni P, Catalano V, et al. Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer. Anticancer Drugs. 2008;19:733–737
  10. Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson B, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol. 1995;13:424–429
  11. Smith IE, A’Hern RP, Coombes GA, Howell A, Ebbs SR, Hickish TF, et al. TOPIC Trial Group. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol. 2004;15:751–758
  12. Rocca A, Peruzzotti G, Ghisini R, Viale G, Veronesi P, Luini A, et al. A randomized phase II trial comparing preoperative plus preoperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. Anticancer Drugs. 2006;10:1201–1209
  13. De Boer RH, Saini A, Johnston RD, O'Brien ME, Ellis PA, Verrill MW, et al. Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study. The Breast. 2000;9:149–155
  14. Markman M, Moon J, Wylczynski S, Lopez AM, Rowland KM, Michelin DP, et al. Single agent carboplatin vs carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol. 2010;116:323–325
  15. Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol. 2003;21:3249–3254
  16. Torrisi R, Bagnardi V, Pruneri G, Ghisini R, Bottiglieri L, Magni E, et al. Antitumor and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer. 2007;97:802–808
  17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST. Eur J Cancer. 2009;45:228–247
  18. Kuerer HM, Newman LA, Smith TM, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–469
  19. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res. 2004;10:6626–6628
  20. Montagna E, Bagnardi V, Rotmensz N, Rodriguez J, Veronesi P, Luini A, et al. Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer. Br J Cancer. 2008;98:1745–1752
  21. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10
  22. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940–1949
  23. Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, et al. Combined modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Center. Cancer Chemother Pharmacol. 1997;40:321–329
  24. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, et al. Inflammatory breast cancer (IBC) and patterns of recurrence:. understanding the biology of a unique disease. Cancer. 2007;110:1436–1444
  25. Dawood S, Broglio K, Kau SW, Islam R, Symmans WF, Buchholz TA, et al. Prognostic value of initial clinical disease stage after achieving pathological complete response. The Oncologist. 2008;13:6–15
  26. Soloman M, Gabizon AA. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. Clin Lymphoma Myeloma. 2008;8:21–32
  27. Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res. 2004;10:7965–7971
  28. D’Alessandro C, Dellapasqua S, Orlando L, Santoro L, Maisonneuve P, Torrisi R, et al. Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy. Breast J. 2008;5:435–441
  29. Colleoni M, Bagnardi V, Rotmensz N, Gelber RD, Viale G, Pruneri G, et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat. 2009;116(2):359–369
  30. Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, et al. Adjuvant and timing of tamoxifen in postmenopausal patients with endocrine-responsive node-positive breast cancer: a phase I3-open-label, controlled trial. Lancet. 2009;374(9707):2055–2063
  31. Von Minckwitz G, Costa SD, Raab G, Blohmer JU, Eidtmann H, Hilfrich J, et al. Dose-dense doxorubicin, docetaxel and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled open phase IIb study. J Clin Oncol. 2001;19:3506–3515
  32. Bottini A, Berruti A, Brizzi MP, Bersiga A, Generali D, Allevi G, et al. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial. Endocr Relat Cancer. 2005;12:383–392
  33. Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol. 2006;24:3623–3628
  34. Torrisi R, Colleoni M, Veronesi P, Rocca A, Peruzzotti G, Severi G, et al. Primary therapy with ECF in combination with a GnRH analogue in premenopausal women with hormone receptor positive T2-T4 breast cancer. The Breast. 2007;16:73–80
  35. Maltezos E, Amarantidis K, Trichas M, Vasiliadis M, Toromanidou M, Chatzaki E, et al. A dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with capecitabine (Xeloda) in patients with refractory solid tumors. Oncology. 2005;69:463–469

PII: S0960-9776(10)00155-4

doi: 10.1016/j.breast.2010.06.005

The Breast
Volume 20, Issue 1 , Pages 34-38 , February 2011

Article Tools